Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3102294 | 0.98 | PLAU (0.57) | PLAUALDH1A1MAPK1TSHRSRD5A2 | |
| SCHEMBL20572734 | 0.88 | TSHR (0.67) | PLAUTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7076662 | 0.80 | ALDH1A1 (0.72) | ALDH1A1TSHRNPC1RAB9ACYP3A4 | |
| SCHEMBL57650 | 0.80 | TSHR (0.79) | ALDH1A1MAPK1TSHRSRD5A2NPC1 | |
| SCHEMBL3374235 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MAPK1TSHRSRD5A2NPC1 | |
| Hydrochloric Acid SCHEMBL5013416 | 0.78 | TSHR (0.76) | ALDH1A1MAPK1TSHRSRD5A2NPC1 | |
| Hydrochloric Acid SCHEMBL30589973 | 0.78 | TSHR (0.76) | ALDH1A1MAPK1TSHRSRD5A2NPC1 | |
| SCHEMBL1581084 | 0.77 | ALDH1A1 (0.55) | ALDH1A1MAPK1TSHRSRD5A2NPC1 | |
| SCHEMBL15139107 | 0.77 | ALDH1A1 (0.55) | ALDH1A1MAPK1TSHRSRD5A2NPC1 | |
| SCHEMBL1581083 | 0.77 | ALDH1A1 (0.55) | ALDH1A1MAPK1TSHRSRD5A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021099518-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN | MODAG GMBH (DE) | 2021-05-27 | — | — | WO | disclosed |
| EP-3409668-B1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2020-10-21 | — | — | EP | disclosed |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-05-28 | — | — | US | disclosed |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-05-28 | — | — | US | disclosed |
| US-20190031645-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-31 | — | — | US | disclosed |
| US-20190031645-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-31 | — | — | US | disclosed |
| EP-3409668-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-05 | — | — | EP | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150080380-A1 | Therapeutic Uses | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
| WO-2001081335-A1 | PYRIMIDINE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001081338-A1 | SUBSTITUTED SULFONYLAMINOPYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-11-01 | — | — | WO | disclosed |
| EP-0934283-A2 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005652-A2 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-02-12 | — | — | WO | disclosed |
| US-5190589-A | Compounds and process preparing a substituted or an unsubstituted 4(5)-(ω-aminoalkyl)imidazole | CEDONA PHARMACEUTICALS B.V. (NL) | 1993-03-02 | — | — | US | disclosed |
| EP-0415948-A1 | PROCESS FOR PREPARING A SUBSTITUTED OR AN UNSUBSTITUTED 4(5)-($g(v)-AMINOALKYL)IMIDAZOLE | CEDONA PHARMACEUTICALS B.V. (NL) | 1991-03-13 | — | — | EP | disclosed |
| WO-1989010360-A1 | PROCESS FOR PREPARING A SUBSTITUTED OR AN UNSUBSTITUTED 4(5)-(omega-AMINOALKYL)IMIDAZOLE | CEDONA PHARMACEUTICALS B.V. (NL) | 1989-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031645-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | MAPKAPK2, MAPKAPK3, MAP3K7 | PLAU 3418/4885ALDH1A1 3644/4885MAPK1 31/4885 |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, G6PC1 | PLAU 1790/4885ALDH1A1 152/4885MAPK1 411/4885 |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | MAPKAPK2, MAPKAPK3, MAP3K7 | PLAU 3111/4885ALDH1A1 3334/4885MAPK1 32/4885 |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | PLAU 3451/4885ALDH1A1 1086/4885MAPK1 1628/4885 |
| US-20150080380-A1 | Therapeutic Uses | HRH3, HRH4, HRH2 | PLAU 2047/4885ALDH1A1 2199/4885MAPK1 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.